Registry and sample resource for patients with plasma cell disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather comprehensive data on patients diagnosed with plasma cell dyscrasias, including multiple myeloma and AL amyloidosis, to enhance their quality of life and longevity. The research involves creating a database that tracks treatment effectiveness, patient experiences, and survival outcomes. Additionally, the study provides patients with access to clinical consultations and information about local support resources. By engaging with patients across Ohio, the investigators hope to develop targeted interventions to reduce morbidity and mortality associated with these conditions.

Why it matters

Who can join: the full rules

Inclusion:

Diagnosis of a plasma cell dyscrasia

Exclusion:

Prisoners are excluded from participation as they have no standard access to the Ohio State myeloma clinic and would impede the research objective of this protocol.

Where it's running

• Ohio State University Medical Center
  Columbus, Ohio, United States Recruiting

Study contacts

• Principal investigator: Don Benson, MD — Ohio State University
• Study coordinator: The Ohio State University Comprehensive Cancer Center
• Email: OSUCCCClinicaltrials@osumc.edu
• Phone: 1-800-293-5066

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SMS text check-ins to track symptoms for people with plasma cell disorders

  This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07850284

• Tec Dara for newly diagnosed multiple myeloma with light chain amyloidosis

  This study tests whether tec listamab plus daratumumab can help newly diagnosed multiple myeloma with AL amyloidosis and whether the combination is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai · NCT07638683

• How the IGLV1-44 light chain causes AL amyloidosis and POEMS

  This project tests whether specific IGLV1-44 light‑chain sequences drive AL amyloidosis and POEMS and whether nanobodies can recognize and stabilize those light chains in adults with AL amyloidosis, POEMS, or multiple myeloma.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07448935

• How N-glycosylation of light chains affects AL amyloidosis diagnosis and treatment

  This project will test whether a sugar modification called N-glycosylation on immunoglobulin light chains helps cause disease or changes how AL amyloidosis and related monoclonal gammopathies behave in adults.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, PV · NCT07448779

• Prolonged overnight fasting combined with a Mediterranean-style diet for people with multiple myeloma or precursor conditions

  This program will test whether longer overnight fasting paired with a Mediterranean-style eating plan is doable for adults with MGUS, smoldering myeloma, or newly diagnosed multiple myeloma who are starting treatment.

  Recruiting University of Miami · Miami, Florida · NCT07446777

• Using Whole Body MRI to Improve Cancer Detection

  This study is testing if Whole Body MRI can help find bone and soft tissue problems in people with different types of cancer, like lymphoma and advanced prostate and breast cancer.

  Recruiting at 2 sites Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Bologna, BO and 2 other locations · NCT06895291

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.